Attached files

file filename
EX-99 - EXHIBIT 99.1 - PDL BIOPHARMA, INC.ex99-1.htm


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): February 7, 2014

 


 

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

 


 

000-19756

(Commission

File Number)

 

   

Delaware

94-3023969

(State or Other Jurisdiction

of Incorporation)

(I.R.S. Employer

Identification No.)

 

932 Southwood Boulevard

Incline Village, Nevada 89451

(Address of principal executive offices, with zip code)

 

(775) 832-8500

(Company’s telephone number, including area code)

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



 

 
 

 

 

Item 8.01 Other Events.

 

On February 7, 2014, PDL BioPharma, Inc. (the “Company”) issued a press release announcing the pricing of an offering of its 4.00% Convertible Senior Notes due February 1, 2018. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

     

Exhibit No.

 

Description

99.1

 

Press Release

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

PDL BIOPHARMA, INC.

 

(Company)

     
 

By:

/s/ Peter S. Garcia

   

Peter S. Garcia

   

Vice President and Chief Financial Officer

 

Dated: February 7, 2014

 

 
 

 

 

EXHIBIT INDEX

 

     

Exhibit No.

 

Description

99.1

 

Press Release